Nyxoah SA (NYXH)
NASDAQ: NYXH · Real-Time Price · USD
6.24
-0.04 (-0.64%)
At close: Aug 29, 2025, 4:00 PM
6.32
+0.08 (1.28%)
After-hours: Aug 29, 2025, 7:01 PM EDT
Nyxoah Revenue
Nyxoah had revenue of 1.34M EUR in the quarter ending June 30, 2025, with 73.80% growth. This brings the company's revenue in the last twelve months to 4.93M, up 2.94% year-over-year. In the year 2024, Nyxoah had annual revenue of 4.52M with 3.98% growth.
Revenue (ttm)
4.93M EUR
Revenue Growth
+2.94%
P/S Ratio
40.29
Revenue / Employee
26,868 EUR
Employees
184
Market Cap
233.40M USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 4.52M | 173.00K | 3.98% |
| Dec 31, 2023 | 4.35M | 1.26M | 40.99% |
| Dec 31, 2022 | 3.08M | 2.23M | 261.97% |
| Dec 31, 2021 | 852.00K | 783.00K | 1,134.78% |
| Dec 31, 2020 | 69.00K | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
NYXH News
- 11 days ago - Nyxoah: High-Risk High-Reward Medtech To Own - Seeking Alpha
- 12 days ago - Nyxoah SA (NYXH) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 12 days ago - Nyxoah Reports Second Quarter Financial and Operating Results - GlobeNewsWire
- 20 days ago - Nyxoah Announces Preliminary Results for the Second Quarter of 2025 - GlobeNewsWire
- 22 days ago - Nyxoah Receives Approval from FDA for Genio® System for the Treatment of Obstructive Sleep Apnea - GlobeNewsWire
- 4 weeks ago - Nyxoah to Release Second Quarter 2025 Financial Results on August 18, 2025 - GlobeNewsWire
- 4 weeks ago - Nyxoah's DREAM Pivotal Study Data Published in the Journal of Clinical Sleep Medicine - GlobeNewsWire
- 2 months ago - Invitation to attend the extraordinary shareholders' meeting of the Company to be held on July 2, 2025 - GlobeNewsWire